David Foster

Teaching Strengths

Pharmacometrics
Modelling and simulation
Pharmacokinetics
Pharmcodynamics
Research skills

APrf David Foster

Associate Professor

School of Pharmacy and Biomedical Sciences

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Available For Media Comment.

My research interests include the optimisation of pharmacotherapeutic treatment of patients through understanding the factors that are responsible for differences in response to medicines between people. This research is primarily focussed on identifying the pharmacokinetic and pharmacodynamic factors which govern variability in drug response. My work aims to employ pharmacometric analysis (modelling and simulation) as a tool to translate basic and clinical research into improved pharmacotherapetic use. Pharmacometrics is the science which deals with the quantitative description of disease, drug effects and variability. The rapidly expanding area of pharmacogenomics is also providing a constant source of genetic differences between people which have major impacts on drug effects and pharmacokinetics. Pharmacometric analyses quantify drug, disease and trial information to aid efficient drug use, development, and regulatory decisions. The strength of such analyses is the ability to integrate knowledge from prior understanding, related compounds and biology, together with the ability to include both richly sampled data and more limited/incomplete data typically unusable in traditional statistical approaches. This area has traditionally been poorly understood by mainstream biomedical researchers. However, this is now changing and increasingly researchers, regulatory authorities and funding bodies are recognizing the power that pharmacometric analyses provide.
 
 
CSIRO
Chair National Health and Medical Human Research Ethics Committee (2024 - present)
 
Population Approach Group of Australia and New Zealand (www.paganz.org)
President (2017 - 2022)
Executive member (2013 - 2016)
Hosted annual meetings in 2017, 2023
Co-hosted annual meetings in 2004 and 2010
Prepared / ran workshops in 2004, 2010, 2015, 2017, 2021, 2023
 
Bellberry Inc Human Research Ethics Committee
Deputy Chair (2025  -present)
Committee member (2013 - present)
Invited Speaker Education Weekend (2022)
 
Children, Youth and Women’s Health Service
Drug Trials sub-committee of the Drug and Therapeutics Committee (2008 - 2024)
 
Australasian Society of Clinical and Experimental Pharmacologists andToxicologists (ASCEPT)
Education forum member (2017 - present)
Drug Disposition and Response special interest group co-chair (2011 - 2018)
Invited speaker Education forum on Undergraduate Research Skills (2022)
Invited speaker "Innovation in the treatment of depression" symposium (2018)
 
Therapeutic Goods Adminstration
Member, Australian Drug Evaluation Committee - Pharmaceutical Sub Committee (2008 - 2017)
Expert Advisor (2018 - present)
 
Editorial Board membership:
British Journal of Pharmacology (2019 - present)
 
Adelaide Pharmacology Group
Executive Member (2006 - present)
 
 

My research interests include the optimisation of pharmacotherapeutic treatment of patients through understanding the factors that are responsible for differences in response to medicines between people. This research is primarily focussed on identifying the pharmacokinetic and pharmacodynamic factors which govern variability in drug response. My work aims to employ pharmacometric analysis (modelling and simulation) as a tool to translate basic and clinical research into improved pharmacotherapetic use. Pharmacometrics is the science which deals with the quantitative description of disease, drug effects and variability. The rapidly expanding area of pharmacogenomics is also providing a constant source of genetic differences between people which have major impacts on drug effects and pharmacokinetics. Pharmacometric analyses quantify drug, disease and trial information to aid efficient drug use, development, and regulatory decisions. The strength of such analyses is the ability to integrate knowledge from prior understanding, related compounds and biology, together with the ability to include both richly sampled data and more limited/incomplete data typically unusable in traditional statistical approaches. This area has traditionally been poorly understood by mainstream biomedical researchers. However, this is now changing and increasingly researchers, regulatory authorities and funding bodies are recognizing the power that pharmacometric analyses provide.

Year Citation
2024 Tan, J. M., Upton, R. N., Foster, D. J. R., Proudman, S. M., Dhir, V., & Wiese, M. D. (2024). Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 90(11), 1-18.
DOI Scopus3 WoS3 Europe PMC1
2022 Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression.. Clin Pharmacol Ther, 112(3), 720-729.
DOI Scopus19 WoS13 Europe PMC11
2022 Manning Bennett, A. T., Hopkins, A. M., Sorich, M. J., Proudman, S. M., Foster, D. J. R., Abuhelwa, A. Y., & Wiese, M. D. (2022). The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials. Therapeutic Advances in Musculoskeletal Disease, 14, 1-14.
DOI Scopus19 WoS18 Europe PMC15
2022 Dumuid, D., Olds, T., Wake, M., Lund Rasmussen, C., Pedišić, Ž., Hughes, J. H., . . . Stanford, T. (2022). Your best day: An interactive app to translate how time reallocations within a 24-hour day are associated with health measures. PLoS One, 17(9), e0272343-1-e0272343-16.
DOI Scopus12 WoS11 Europe PMC10
2022 Kamel, B., Abuhelwa, A. Y., Foster, D., Duong, J. K., Graham, G. G., Williams, K. M., . . . Day, R. O. (2022). Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout. British Journal of Clinical Pharmacology, 88(12), 5359-5368.
DOI Scopus5 WoS5 Europe PMC7
2021 Ladebo, L., Abuhelwa, A. Y., Foster, D. J. R., Kroustrup, J. P., Pacyk, G. J., Kongstad, K. T., . . . Olesen, A. E. (2021). Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. Basic and Clinical Pharmacology and Toxicology, 129(3), 232-245.
DOI Scopus9 WoS9 Europe PMC5
2021 Abuhelwa, A. Y., Foster, D. J. R., Manning Bennett, A., Sorich, M. J., Proudman, S., Wiese, M. D., & Hopkins, A. M. (2021). Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. Therapeutic Advances in Musculoskeletal Disease, 13, 1-7.
DOI Scopus2 WoS2 Europe PMC1
2020 Abuhelwa, A. Y., Hopkins, A. M., Sorich, M. J., Proudman, S., Foster, D. J. R., & Wiese, M. D. (2020). Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Scientific Reports, 10(18634), 1-9.
DOI Scopus35 WoS32 Europe PMC26
2020 Nøhr-Nielsen, A., Lange, T., Forman, J. L., Papathanasiou, T., Foster, D. J. R., Upton, R. N., . . . Lund, T. M. (2020). Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis. AAPS Journal, 22(2), 14 pages.
DOI Scopus2 WoS2 Europe PMC2
2020 Ladebo, L., Foster, D. J. R., Abuhelwa, A. Y., Upton, R. N., Kongstad, K. T., Drewes, A. M., . . . Olesen, A. E. (2020). Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 126(3), 263-276.
DOI Scopus16 WoS13 Europe PMC11
2020 Wang, M., Foster, D. J., & Pfeiffer, B. E. (2020). Alternating sequences of future and past behavior encoded within hippocampal theta oscillations. SCIENCE, 370(6513), 247-+.
DOI WoS78
2019 Hennig, S., Hannam, J. A., Kirkpatrick, C. M. J., Staatz, C. E., Holford, S., Duffull, S. B., . . . Foster, D. J. R. (2019). Pharmacometrics in Australasia—Twenty Years of Population Approach Group of Australia and New Zealand. Cpt Pharmacometrics and Systems Pharmacology, 8(10), 701-704.
DOI Scopus6 WoS6 Europe PMC4
2019 Hughes, J. H., Upton, R. N., Reuter, S. E., Rozewski, D. M., Phelps, M. A., & Foster, D. J. R. (2019). Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer Chemotherapy and Pharmacology, 84(5), 1073-1087.
DOI Scopus8 WoS8 Europe PMC8
2019 Hughes, J. H., Upton, R. N., Reuter, S. E., Phelps, M. A., & Foster, D. J. R. (2019). Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. Journal of pharmacy and pharmacology, 71(11), 1635-1644.
DOI Scopus10 WoS11 Europe PMC9
2019 Abuhelwa, A. Y., Mudge, S., Upton, R. N., & Foster, D. J. R. (2019). Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 44(2), 201-215.
DOI Scopus11 WoS9 Europe PMC8
2019 Hughes, J. H., Phelps, M. A., Upton, R. N., Reuter Lange, S. E., Gao, Y., Byrd, J. C., . . . Foster, D. J. R. (2019). Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. British journal of clinical pharmacology, 85(5), 924-934.
DOI Scopus13 WoS11 Europe PMC13
2018 Petito, E. S., Foster, D. J. R., Ward, M. B., & Sykes, M. J. (2018). Molecular modeling approaches for the prediction of selected pharmacokinetic properties. Current topics in medicinal chemistry, 18(26), 2230-2238.
DOI Scopus2 WoS2 Europe PMC1
2018 Abuhelwa, A. Y., Mudge, S., Upton, R. N., & Foster, D. J. R. (2018). Population in vitro–in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. Journal of Pharmacokinetics and Pharmacodynamics, 45(2), 181-197.
DOI Scopus7 WoS7 Europe PMC6
2018 Boone, C. E., Davoudi, H., Harrold, J. B., & Foster, D. J. (2018). Abnormal Sleep Architecture and Hippocampal Circuit Dysfunction in a Mouse Model of Fragile X Syndrome. NEUROSCIENCE, 384, 275-289.
DOI WoS31
2017 Hughes, J. H., Reuter, S. E., Upton, R. N., Phelps, M., & Foster, D. J. R. (2017). Population pharmacokinetics of lenalidomide in patients with haematological cancer. Journal of Pharmacokinetics and Pharmacodynamics, 44(S1), 72.
2017 Hopkins, A., Moghaddami, M., Foster, D., Proudman, S., Upton, R., & Wiese, M. (2017). Intracellular CD3⁺ T-lymphocyte teriflunomide concentration is poorly correlated with and has greater variability than unbound plasma teriflunomide concentration. Drug Metabolism Disposition, 45(1), 8-16.
DOI Scopus10 WoS10 Europe PMC9
2017 Abuhelwa, A. Y., Williams, D. B., Upton, R. N., & Foster, D. J. R. (2017). Food, gastrointestinal pH, and models of oral drug absorption. European Journal of Pharmaceutics and Biopharmaceutics, 112, 234-248.
DOI Scopus298 WoS246 Europe PMC182
2017 Hopkins, A. M., Wojciechowski, J., Abuhelwa, A. Y., Mudge, S., Upton, R. N., & Foster, D. J. R. (2017). Population pharmacokinetic model of doxycycline plasma concentrations using pooled study data. Antimicrobial agents and chemotherapy, 61(3, article no. e02401-16), 1-15.
DOI Scopus11 WoS10 Europe PMC8
2017 Bazargan, M., Foster, D., Davey, A., & Muhlhausler, B. (2017). Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. Drugs in R and D, 17(1), 189-198.
DOI Scopus11 WoS11 Europe PMC8
2017 Hughes, J. H., Upton, R. N., & Foster, D. J. R. (2017). Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations. Journal of pharmacokinetics and pharmacodynamics, 44(3), 233-244.
DOI Scopus7 WoS7 Europe PMC6
2017 Wojciechowski, J., Upton, R. N., Mould, D. R., Wiese, M. D., & Foster, D. J. R. (2017). Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies. AAPS Journal, 19(4), 1136-1147.
DOI Scopus33 WoS33 Europe PMC26
2017 Leshinsky, J., McLachlan, A., Foster, D. J. R., Norris, R., & Barrs, V. R. (2017). Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats. PL o S one, 12(5, article no. e0178783), 1-14.
DOI Scopus11 WoS8 Europe PMC6
2016 Knøsgaard, K. R., Foster, D. J. R., Kreilgaard, M., Sverrisdóttir, E., Upton, R. N., & van den Anker, J. N. (2016). Pharmacokinetic models of morphine and its metabolites in neonates: Systematic comparisons of models from the literature, and development of a new meta-model. European journal of pharmaceutical sciences, 92, 117-130.
DOI Scopus31 WoS30 Europe PMC29
2016 Abuhelwa, A., Foster, D., & Upton, R. (2016). A quantitative review and meta-models of the variability and factors affecting oral drug absorption-Part II: gastrointestinal transit time. AAPS Journal, 18(5), 1322-1333.
DOI Scopus73 WoS36 Europe PMC46
2016 Abuhelwa, A., Foster, D., & Upton, R. (2016). A quantitative review and meta-models of the variability and factors affecting oral drug absorption-Part I: gastrointestinal pH. AAPS Journal, 18(5), 1309-1321.
DOI Scopus101 WoS109 Europe PMC70
2016 Upton, R. N., Foster, D. J. R., & Abuhelwa, A. Y. (2016). An introduction to physiologically-based pharmacokinetic models. Paediatric anaesthesia, 26(11), 1036-1046.
DOI Scopus46 WoS35 Europe PMC30
2016 Yata, M., McLachlan, A., Foster, D., Hanzlicek, A., & Beijerink, N. (2016). Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats. Journal of Veterinary Cardiology, 18(4), 310-325.
DOI Scopus28 WoS28 Europe PMC19
2016 Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2016). A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 81(6), 1046-1057.
DOI Europe PMC1
2016 Olsen, R., Foster, D. J. R., Upton, R. N., Olesen, A. E., Ross, J. R., Droney, J., . . . Kreilgaard, M. (2016). Modelling the PKPD of oxycodone in experimental pain - Impact of opioid receptor polymorphisms. European Journal of Pharmaceutical Sciences, 86, 41-49.
DOI Scopus6 WoS4 Europe PMC2
2016 Bazargan, M., Foster, D., Muhlhausler, B., Morrison, J., McMillen, C., & Davey, A. (2016). Limited fetal metabolism of rosiglitazone: elimination via the maternal compartment in the pregnant ewe. Reproductive Toxicology, 61, 162-168.
DOI Scopus8 WoS5 Europe PMC4
2016 Abuhelwa, A., Mudge, S., Hayes, D., Upton, R., & Foster, D. (2016). Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. Pharmaceutical Research, 33(7), 1782-1794.
DOI Scopus32 WoS26 Europe PMC21
2016 Hopkins, A., Wiese, M., Proudman, S., O'Doherty, C., Upton, R., & Foster, D. (2016). Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 81(1), 113-123.
DOI Scopus20 WoS14 Europe PMC13
2016 Yata, M., McLachlan, A., Foster, D., Page, S., & Beijerink, N. (2016). Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics, 39(1), 45-53.
DOI Scopus23 WoS20 Europe PMC15
2015 Sverrisdottir, E., Foster, D., Upton, R., Olesen, A., Lund, T., Gabel-Jensen, C., . . . Kreilgaard, M. (2015). Modelling concentration-analgesia relationships for morphine to evaluate experimental pain models. European Journal of Pharmaceutical Sciences, 66, 50-58.
DOI Scopus16 WoS17 Europe PMC10
2015 Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2015). A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. British journal of clinical pharmacology, 79(5), 777-788.
DOI Scopus6 WoS5 Europe PMC6
2015 Hopkins, A. M., Foster, D., Wiese, M., & Upton, R. (2015). Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide - Should Consideration Be Given to Cannalicular Efflux Transporters?. CPT: Pharmacometrics and Systems Pharmacology, 4(10), 564.
DOI
2015 Abuhelwa, A., Foster, D., & Upton, R. (2015). ADVAN-style analytical solutions for common pharmacokinetic models. Journal of Pharmacological and Toxicological Methods, 73, 42-48.
DOI Scopus8 WoS7 Europe PMC4
2015 Hopkins, A., Wiese, M., Proudman, S., O'Doherty, C., Foster, D., & Upton, R. (2015). Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients. CPT: Pharmacometrics and Systems Pharmacology, 4(6), 362-371.
DOI Scopus17 WoS16 Europe PMC11
2015 Abuhelwa, A., Foster, D., Mudge, S., Hayes, D., & Upton, R. (2015). Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrobial Agents and Chemotherapy, 59(9), 5681-5696.
DOI Scopus104 WoS87 Europe PMC73
2014 Ravn, P., Foster, D., Kreilgaard, M., Christrup, L., Werner, M., Secher, E., . . . Upton, R. (2014). Pharmacokinetic-pharmacodynamic modelling of the analgesic and antihyperalgesic effects of morphine after intravenous infusion in human volunteers. Basic and Clinical Pharmacology and Toxicology, 115(3), 257-267.
DOI Scopus7 WoS7 Europe PMC5
2014 Ravn, P., Foster, D. J. R., Kreilgaard, M., Christrup, L., Werner, M., Secher, E., . . . Upton, R. (2014). Pharmacokinetic-Pharmacodynamic Modelling of the Analgesic and Anti-hyperalgesic Effects of Morphine after Intravenous Infusion in Human Volunteers (vol 115, pg 257, 2014). BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 115(5), 476.
DOI
2014 Juul, R., Foster, D., Upton, R., Andresen, T., Graversen, C., Drewes, A., . . . Kreilgaard, M. (2014). Pharmacodynamic modelling of placebo and buprenorphine effects on event-related potentials in experimental pain. Basic and Clinical Pharmacology and Toxicology, 115(4), 343-351.
DOI Scopus4 WoS5 Europe PMC4
2014 Hopkins, A. M., O'Doherty, C. E., Foster, D. J. R., Upton, R. N., Proudman, S. M., & Wiese, M. D. (2014). Individualization of leflunomide dosing in rheumatoid arthritis patients. Personalized Medicine, 11(4), 449-461.
DOI Scopus7 WoS8 Europe PMC5
2014 Hopkins, A., O'Doherty, C., Foster, D., Suppiah, V., Upton, R., Spargo, L., . . . Wiese, M. (2014). The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. Journal of Clinical Pharmacy and Therapeutics, 39(5), 555-560.
DOI Scopus6 WoS5 Europe PMC4
2013 Upton, R. N., Foster, D. J. R., Christrup, L. L., Dale, O., Moksnes, K., & Popper, L. (2013). Erratum to: A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics, 40(2), 253.
DOI
2013 Lewis, A., Holden, R., Chung, S., Czuczman, P., Kuchel, T., Finnie, J., . . . Foster, D. (2013). Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. Journal of Materials Science-Materials in Medicine, 24(1), 115-127.
DOI Scopus18 WoS18 Europe PMC16
2012 Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62.
DOI Scopus49 WoS44 Europe PMC39
2012 Upton, R., Foster, D., Christrup, L., Dale, O., Moksnes, K., & Popper, L. (2012). A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics, 39(5), 561-576.
DOI Scopus12 WoS12 Europe PMC10
2011 Andresen, T., Upton, R., Foster, D., Christrup, L., Arendt-Nielsen, L., & Drewes, A. (2011). Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. Basic and Clinical Pharmacology and Toxicology, 108(4), 274-284.
DOI Scopus40 WoS32 Europe PMC32
2011 Ward, M., & Foster, D. (2011). CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradication. European Journal of Clinical Pharmacology, 67(3), 261-266.
DOI Scopus3 WoS3 Europe PMC3
2011 Bazargan, M., Davey, A., Muhlhausler, B., Morrison, J., McMillen, I., & Foster, D. (2011). Simple HPLC method for determination of rosiglitazone in sheep plasma and amniotic fluid and its application in a pregnant sheep model. Journal of Pharmaceutical and Biomedical Analysis, 55(2), 360-365.
DOI Scopus13 WoS13 Europe PMC9
2010 Olesen, A., Upton, R., Foster, D., Staahl, C., Christrup, L., Arendt-Nielsen, L., & Drewes, A. (2010). A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. Clinical Pharmacokinetics, 49(12), 817-827.
DOI Scopus25 WoS23 Europe PMC20
2010 Gordon, A., Lopatko, O., Somogyi, A., Foster, D., & White, J. (2010). (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology, 70(6), 895-902.
DOI Scopus31 WoS29 Europe PMC25
2008 Foster, D., Upton, R., Christrup, L., & Popper, L. (2008). Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Annals of Pharmacotherapy, 42(10), 1380-1387.
DOI Scopus98 WoS85 Europe PMC71
2008 Jensen, M., Sjogren, P., Upton, R., Foster, D., Bonde, P., Graae, C., . . . Christrup, L. (2008). Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic ' Clinical Pharmacology ' Toxicology, 103(1), 94-101.
DOI Scopus25 WoS25 Europe PMC20
2008 Christrup, L., Foster, D., Popper, L., Troen, T., & Upton, R. (2008). Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clinical Therapeutics, 30(3), 469-481.
DOI Scopus125 WoS104 Europe PMC84
2008 Staahl, C., Upton, R., Foster, D., Christrup, L., Kristensen, K., Hansen, S., . . . Drewes, A. (2008). Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. Journal of Clinical Pharmacology, 48(5), 619-631.
DOI Scopus60 WoS52 Europe PMC46
2007 Coller, J., Joergensen, C., Foster, D., James, H., Gillis, D., Christrup, L., & Somogyi, A. (2007). Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon. International Journal of Clinical Pharmacology and Therapeutics, 45(7), 410-417.
DOI Scopus25 WoS22 Europe PMC19
2007 Jensen, M., Foster, D., Upton, R., Kristensen, K., Hansen, S., Jensen, N., . . . Christrup, L. (2007). Population pharmacokinetics of buprenorphine following a two-stage intravenous infusion in healthy volunteers. European Journal of Clinical Pharmacology, 63(12), 1153-1159.
DOI Scopus18 WoS16 Europe PMC15
2007 Jensen, M., Foster, D., Upton, R., Grant, C., Martinez, A., & Somogyi, A. (2007). Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica, 37(4), 441-457.
DOI Scopus22 WoS20 Europe PMC20
2007 XU, M., Chen, W. Q., Wang, J., Foster, D. J. R., & Xu, D. (2007). 5-HT3 receptors in the central amygdala mediate the modulation of thymus function in rats. Acta physiologica sinica, 59(1), 42-50.
Scopus1 Europe PMC1
2007 Xu, D., Zhang, S., Foster, D. J. R., & Wang, J. (2007). The effects of isosteviol against myocardium injury induced by ischaemia-reperfusion in the isolated guinea pig heart. Clinical and experimental pharmacology and physiology, 34(5-6), 488-493.
DOI Scopus35 WoS35 Europe PMC23
2006 Upton, R., Semple, T., Macintyre, P., & Foster, D. (2006). Population pharmacokinetic modelling of subcutaneous morphine in the elderly. Acute Pain, 8(3), 109-116.
DOI Scopus12
2006 Villesen, H., Foster, D., Upton, R., Christrup, L., Somogyi, A., Martinez, A., & Grant, C. (2006). Blood-brain distribution of morphine-6-glucuronide in sheep. British Journal of Pharmacology, 149(6), 754-760.
DOI Scopus3 WoS3 Europe PMC1
2006 Foster, D., Morton, E., Heinkele, G., Murdter, T., & Somogyi, A. (2006). Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: Application to a pharmacokinetic study in a methadone maintained subject. Therapeutic Drug Monitoring, 28(4), 559-567.
DOI Scopus13 WoS11 Europe PMC11
2006 Villesen, H., Foster, D., Upton, R., Somogyi, A., Martinez, A., & Grant, C. (2006). Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences, 95(8), 1666-1676.
DOI Scopus24 WoS23 Europe PMC21
2006 Foster, D., Jensen, M., Upton, R., Somogyi, A., Grant, C., & Martinez, A. (2006). Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation. British Journal of Pharmacology, 147(2), 209-217.
DOI Scopus3 WoS3 Europe PMC3
2006 Morrish, G., Foster, D., & Somogyi, A. (2006). Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. British Journal of Clinical Pharmacology, 61(3), 326-335.
DOI Scopus16 WoS17 Europe PMC14
2005 Foster, D., Upton, R., Somogyi, A., Grant, C., & Martinez, A. (2005). The acute disposition of (R)- and (S)-methadone in brain and lung of sheep. Journal of Pharmacokinetics and Pharmacodynamics, 32(3-4), 547-570.
DOI Scopus9 WoS8 Europe PMC7
2005 Hanna, J., Foster, D., Salter, A., Somogyi, A., White, J., & Bochner, F. (2005). Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. British Journal of Clinical Pharmacology, 60(4), 404-413.
DOI Scopus24 WoS23 Europe PMC17
2004 Jittiwutikarn, J., Ali, R., White, J., Bochner, F., Somogyi, A., & Foster, D. (2004). Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 58(5), 536-541.
DOI Scopus20 WoS17 Europe PMC11
2004 Foster, D., Somogyi, A., White, J., & Bochner, F. (2004). Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 57(6), 742-755.
DOI Scopus72 WoS61 Europe PMC52
2004 Hutchinson, M., Menelaou, A., Foster, D., Coller, J., & Somogyi, A. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57(3), 287-297.
DOI Scopus143 WoS107 Europe PMC87
2004 Somogyi, A., Bochner, F., & Foster, D. (2004). Inside the isomers: the tale of chiral switches. Australian Prescriber, 27(2), 47-49.
DOI Scopus36
2002 Olver, I., Hercus, T., Lopez, A., Vadas, M., Somogyi, A., Doyle, I., . . . Wigley, P. (2002). A phase I study of the GM-CSF antagonist E21R. Cancer Chemotherapy and Pharmacology, 50(3), 171-178.
DOI Scopus8 WoS8 Europe PMC7
2001 Dyer, K., White, J., Foster, D., Bochner, F., Menelaou, A., & Somogyi, A. (2001). The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology, 21(1), 78-84.
DOI Scopus66 WoS55 Europe PMC45
2000 Foster, D., Somogyi, A., & Bochner, F. (2000). Stereoselective quantification of methadone and its major oxidative metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, in human urine using high-performance liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 744(1), 165-176.
DOI Scopus34 WoS32 Europe PMC21
2000 Foster, D., Somogyi, A., Dyer, K., White, J., & Bochner, F. (2000). Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 50(5), 427-440.
DOI Scopus126 WoS107 Europe PMC87
1999 Dyer, K., Foster, D., White, J., Somogyi, A., Menelaou, A., & Bochner, F. (1999). Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 65(6), 685-694.
DOI Scopus130 WoS117 Europe PMC95
1999 Foster, D., Somogyi, A., & Bochner, F. (1999). Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.. British Journal of Clinical Pharmacology, 47(4), 403-412.
DOI Scopus178 WoS157 Europe PMC123
1995 Sallustio, B., & Foster, D. (1995). Reactivity of gemfibrozil 1-0-b acyl glucuronide: Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. Drug Metabolism and Disposition, 23(9), 892-899.
DOI Scopus29 WoS26 Europe PMC11

Year Citation
2007 Somogyi, A., Culler, J., Hallinan, R., & Foster, D. (2007). Pharmacokinetics and pharmacogenomics of high dose methadone in maintenance subjects. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 485-486). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS.
2006 Somogyi, A., Nguyen, M., Lopatko, O., Foster, D., & White, J. (2006). Comparison of pharmacokinetics and pharmacodynamics of R-, S- and racemic-methadone in healthy subjects. In ACTA PHARMACOLOGICA SINICA Vol. 27 (pp. 418). BLACKWELL PUBLISHING.
2005 Morrish, G. A., Somogyi, A. A., & Foster, D. J. R. (2005). Population pharmacokinetic analysis of morphine in opioid dependent and control subjects. In DRUG METABOLISM REVIEWS Vol. 37 (pp. 60). Nice, FRANCE: TAYLOR & FRANCIS INC.

Year Citation
2016 Sverrisdóttir, E., Foster, D. J. R., Olesen, A. E., Lund, T. M., Drewes, A. M., Christrup, L. L., . . . Upton, R. N. (2016). Pharmacokinetic metamodel of morphine and morphine-6-glucuronide in neonates and adults. Poster session presented at the meeting of Abstracts of the Annual Meeting of the Population Approach Group in Europe. Portugal: PAGE.
2015 Wojciechowski, J., Wiese, M., Proudman, S., Foster, D., & Upton, R. (2015). A SYSTEMATIC EVALUATION OF SINGLE MEASURES IN DISCRIMINATING CHANGES IN RHEUMATOID ARTHRITIS DISEASE ACTIVITY. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY-BLACKWELL.
2011 Somogyi, A. A., Coller, J. K., Foster, D. B. F., & Li, Y. (2011). ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS. Poster session presented at the meeting of BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. WILEY-BLACKWELL.
WoS1
2000 Olver, I., Vadas, M., Lopez, A., Keefe, D., Taylor, A., Brown, M., & To, L. (2000). A phase 1 study of the GM-CSF antagonist E21R. Poster session presented at the meeting of Proceedings of ASCO - Volume 19 2000. USA: American Society of Clinical Oncology.
DOI
  • Product Evaluation Services – Pop PK Evaluation under Panel arrangement, Therapeutic Goods Administration, 16/04/2025 - 15/05/2028
  • Product Evaluation Services – Pop PK Evaluation, Therapeutic Goods Administration, 04/04/2019 - 01/06/2024
  • Medical and advisory services, Therapeutic Goods Administration, 01/01/2014 - 31/12/2020
  • Model based methods to predict clinical drug exposure from formulation characteristics, Mayne Pharma Pty Ltd, 10/07/2017 - 09/07/2020

Courses I teach

  • PHAR 2006 Pharmacokinetics and Biopharmaceutics (2026)
  • PHAR 4030 Pharmacy and Pharmaceutical Science Research Elective (2026)
  • RESE 5002 Research Integrity and Ethics (2026)
  • PHAR 2006 Pharmacokinetics and Biopharmaceutics (2025)
  • PHAR 3017 Pharmacokinetic-Pharmacodynamic Modelling (2025)
  • PHAR 4030 Pharmacy and Pharmaceutical Science Research Elective (2025)

Date Role Research Topic Program Degree Type Student Load Student Name
2019 Co-Supervisor Development of ex vivo models to predict the efficacy of disease modifying agents in rheumatoid arthritis Doctor of Philosophy Doctorate Full Time Mr Arkady Tobias Manning-Bennett
2018 Co-Supervisor A computational approach to improve the prediction of fraction unbound to enhance pharmacokinetic (PK) and biopharmaceutic models Doctor of Philosophy Doctorate Part Time Mr Emilio Petito

Connect With Me

External Profiles

Other Links